Agamree is an innovative glucocorticoid drug primarily composed of Vamorolone, developed by Santhera Pharmaceuticals in Switzerland. This drug is specifically designed to treat Duchenne muscular dystrophy (DMD) in patients aged 2 years and above, and is the first fully approved drug in the European Union for the treatment of DMD. Agamree is administered in the form of an oral suspension.
What is Agamree medicine
Agamree is a novel glucocorticoid drug that provides innovative treatment options for patients with Duchenne muscular dystrophy.
medicinal property
The main active ingredient Vamorolone is a selective glucocorticoid receptor modulator with improved safety characteristics compared to traditional glucocorticoids. The drug is an orange flavored white to light milky white suspension with a concentration of 40mg/ml. The packaging includes a 100ml glass bottle, a dedicated oral syringe, etc.
R&D Background
Developed by Swiss company Santhera Pharmaceuticals, it was first launched in Germany in January 2024. As the first fully approved DMD treatment drug in the European Union, Agamree breaks through the limitations of traditional glucocorticoid therapy and provides patients with a safer option.
Functional characteristics
Vamorolone retains the anti-inflammatory effects of traditional glucocorticoids while reducing some adverse reactions. Medications improve muscle function and inflammatory status in DMD patients through multiple mechanisms, and are suitable for DMD patients of various genotypes. Agamree represents an important breakthrough in the field of DMD treatment, providing patients with safer and more effective treatment options.
Agamree treatment effect
Clinical studies have confirmed that Agamree has significant therapeutic effects on Duchenne muscular dystrophy.
clinical efficacy
In key clinical trials, Agamree significantly improved motor function in DMD patients. The 6mg/kg dose group showed an average improvement of 25 meters in 6-minute walking distance and a significant improvement in muscle strength assessment. Compared to traditional glucocorticoids, the incidence of adverse bone reactions is reduced.
Treatment advantages
The once daily dosing regimen is simple and easy to implement. Drug absorption is not significantly affected by diet, and patient compliance is high. Effective for DMD patients aged 4 and above at all stages, regardless of the type of genetic mutation.
Long term benefits
Long term use can delay disease progression and maintain patients' motor function. Compared with traditional hormones, long-term side effects such as growth inhibition and abnormal bone metabolism are significantly reduced, improving the quality of life of patients. Agamree provides a safer and more effective long-term treatment plan for DMD patients through its unique pharmacological properties.
Agamree storage method
The correct storage method is crucial for maintaining drug stability and efficacy.
Unopened storage
It should be stored upright in the original packaging at room temperature of 20-25 ° C, and short-term storage at 15-30 ° C is allowed. Avoid direct sunlight and high temperature environments to prevent degradation of drug ingredients.
Handling after opening
After opening, it should be stored upright in a refrigerator at 2-8 ° C and not frozen. Shake well for 30 seconds before each use and accurately measure with a dedicated syringe. If not used within 3 months after opening the bottle, it should be discarded.
Special case handling
When traveling, special medication boxes can be used for short-term carrying to avoid severe shaking. If the suspension is found to be stratified, discolored, or has an odor, it should be stopped from use. Medications should be kept out of reach of children.
Following the correct storage method can help Agamree maintain optimal efficacy and safety throughout its entire use.
